Loading…
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature. The company also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; and TransCyte, a bioengineered tissue scaffold that promotes burn healing. In addition, it develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. The company serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $563M | $83M | $37M | $-24M | 8.5% | 16.8% | 4201.0% |
| 2024 | $482M | $24M | $1M | $4M | 0.2% | 11.3% | -82.6% |
| 2023 | $433M | $36M | $5M | $7M | 1.8% | -3.9% | -68.2% |
| 2022 | $451M | $40M | $16M | $-9M | 5.8% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 450.89 | 433.14 | 482.04 | 563.03 |
| Cost Of Revenue | 105.02 | 106.48 | 115.74 | 137.52 |
| Gross Profit | 345.87 | 326.66 | 366.30 | 425.51 |
| Operating Expense | 323.57 | 314.13 | 344.78 | 369.64 |
| Operating Income | 22.30 | 12.53 | 21.52 | 55.87 |
| EBITDA | 40.32 | 36.03 | 24.11 | 82.81 |
| EBIT | 22.29 | 12.58 | -1.26 | 55.87 |
| Pretax Income | 20.28 | 10.39 | -2.81 | 46.97 |
| Tax Provision | 4.75 | 5.45 | -3.67 | 9.94 |
| Net Income | 15.53 | 4.95 | 0.86 | 37.03 |
| Net Income Common Stockholders | 15.53 | 4.95 | -0.94 | 20.02 |
| Total Expenses | 428.59 | 420.62 | 460.52 | 507.16 |
| Interest Expense | 2.01 | 2.19 | 1.54 | 0 |
| Interest Income | 0 | 0 | 0 | 2.28 |
| Research And Development | 39.76 | 44.38 | 50.27 | 44.54 |
| Selling General And Administration | 283.81 | 269.75 | 294.51 | 326.24 |
| Normalized EBITDA | 40.32 | 36.03 | 46.91 | 93.98 |
| Normalized Income | 15.53 | 4.95 | 18.87 | 45.84 |
| Basic EPS | 0.12 | 0.04 | -0.01 | 0.16 |
| Diluted EPS | 0.12 | 0.04 | -0.01 | 0.15 |
| Tax Effect Of Unusual Items | 0 | 0 | -4.79 | -2.37 |
| Tax Rate For Calcs | 0.23 | 0.21 | 0.21 | 0.21 |
| Total Unusual Items | 0 | 0 | -22.80 | -11.18 |
| Total Unusual Items Excluding Goodwill | 0 | 0 | -22.80 | -11.18 |
| Net Income From Continuing Operation Net Minority Interest | 15.53 | 4.95 | 0.86 | 37.03 |
| Reconciled Depreciation | 18.03 | 23.45 | 25.37 | 26.94 |
| Reconciled Cost Of Revenue | 105.02 | 106.48 | 115.74 | 137.52 |
| Net Interest Income | -2.01 | -2.19 | -1.54 | 2.28 |
| Net Income From Continuing And Discontinued Operation | 15.53 | 4.95 | 0.86 | 37.03 |
| Total Operating Income As Reported | 22.30 | 12.53 | -1.28 | 44.69 |
| Diluted Average Shares | 132.38 | 132.75 | 131.67 | 130.25 |
| Basic Average Shares | 130.07 | 131.23 | 131.67 | 126.74 |
| Diluted NI Availto Com Stockholders | 15.53 | 4.95 | -0.94 | 20.02 |
| Otherunder Preferred Stock Dividend | 0 | 0 | 0.41 | 6.18 |
| Preferred Stock Dividends | 0 | 0 | 1.39 | 10.83 |
| Net Income Including Noncontrolling Interests | 15.53 | 4.95 | 0.86 | 37.03 |
| Net Income Continuous Operations | 15.53 | 4.95 | 0.86 | 37.03 |
| Other Income Expense | -0.01 | 0.06 | -22.78 | -11.18 |
| Other Non Operating Income Expenses | -0.01 | 0.06 | 0.02 | -0.01 |
| Special Income Charges | 0 | 0 | -22.80 | -11.18 |
| Other Special Charges | 0 | 0 | 0 | 0 |
| Write Off | 0 | 0 | 3.96 | 0 |
| Impairment Of Capital Assets | 0 | 0 | 18.84 | 11.18 |
| Restructuring And Mergern Acquisition | 0 | 0 | 0 | 0 |
| Net Non Operating Interest Income Expense | -2.01 | -2.19 | -1.54 | 2.28 |
| Interest Expense Non Operating | 2.01 | 2.19 | 1.54 | 0 |
| Interest Income Non Operating | 0 | 0 | 0 | 2.28 |
| Other Operating Expenses | 0 | 0 | 0 | -1.14 |
| Operating Revenue | 450.89 | 433.14 | 482.04 | 563.03 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Organogenesis Holdings Inc.this co. | ORGO | $296M | 15.33 | 0.97 | 8.5% | 5.55 |
| Anavex Life Sciences Corp. | AVXL | $302M | - | 2.39 | -48.9% | - |
| Compass Therapeutics, Inc. | CMPX | $301M | - | 1.51 | -33.8% | -1.40 |
| Greenwich LifeSciences, Inc. | GLSI | $299M | - | 136.71 | -623.1% | -15.09 |
| Rezolute, Inc. | RZLT | $299M |
| - |
| 2.53 |
| -45.9% |
| -1.89 |
| Protara Therapeutics, Inc. | TARA | $285M | - | 1.41 | -29.2% | -1.99 |
| LENZ Therapeutics, Inc. | LENZ | $284M | - | 1.00 | -28.9% | 0.09 |
| Simulations Plus, Inc. | SLP | $283M | - | 2.11 | -51.9% | 17.29 |
| RxSight, Inc. | RXST | $282M | - | 1.02 | -14.1% | -1.42 |
| Peer Median | - | - | 1.81 | -39.8% | -1.42 | |